BCMA CAR-T FOR MYELOMA
IN INDIA: 2026 STATUS
India's CAR-T commercial landscape covers CD19 today โ BCMA for myeloma is in the pipeline but not yet available. Patients with relapsed myeloma needing CAR-T have better access through China in 2026.
analyticsAt a Glance
- check_circleNexCAR19 targets CD19 only โ myeloma patients are not eligible
- check_circleNo BCMA CAR-T commercially approved in India as of 2026
- check_circleImmunoACT BCMA programme in development โ projected 2027โ2028 earliest
- check_circleChina offers commercial BCMA CAR-T and dual-target trials now
Why BCMA CAR-T Is Not Yet Available in India
NexCAR19, India's only commercially approved CAR-T product, targets CD19 โ a surface protein expressed on B-cell lymphomas and leukaemias. Myeloma is a plasma cell malignancy that overexpresses BCMA (B-cell maturation antigen), not CD19.
Different Disease Target
Multiple myeloma plasma cells express BCMA (TNFRSF17) and GPRC5D, not CD19. A CD19 CAR-T product has no therapeutic mechanism against myeloma โ a fundamentally different disease biology.
ImmunoACT BCMA Pipeline
ImmunoACT (the maker of NexCAR19) has publicly disclosed a BCMA CAR-T development programme for myeloma. As of 2026, this programme is at pre-clinical to early Phase I stage โ not yet commercially available.
Other Indian Biotech
Other Indian biotechs including Immunovant and BioAtrox have disclosed myeloma-focused CAR-T research programmes. These are earlier stage than ImmunoACT's BCMA construct and commercial timelines are undefined.
Timeline Projection
The earliest realistic timeline for Indian commercial BCMA CAR-T is 2027โ2028, accounting for Phase I completion, Phase II enrolment, CDSCO review, and manufacturing scale-up. This is an estimate and may shift.
What Myeloma Options Are Available in India Today?
While BCMA CAR-T is not available, India does offer world-class access to other advanced myeloma therapies at a fraction of Western costs.
Daratumumab Biosimilar
Darzalex (daratumumab) biosimilar is available in India at $2,000โ4,000 per cycle compared to $15,000+ in the USA. This is a major cost advantage for myeloma patients from lower-income countries.
Bortezomib and Lenalidomide Generics
Generic bortezomib (Velcade biosimilar) and lenalidomide are widely available at Indian pricing โ dramatically cheaper than in Western markets. VRd and DRd regimens are standard of care at leading Indian myeloma centres.
Isatuximab (Sarclisa)
Isatuximab-irfc is available at select Indian centres. Access has expanded with recent CDSCO approvals. Price is significantly lower than in USA/EU but higher than biosimilar daratumumab.
Autologous SCT
Autologous stem cell transplant is widely performed across Indian transplant centres (AIIMS, CMC Vellore, Apollo, Manipal, TMC) โ a key component of myeloma management that remains accessible and affordable.
Myeloma Treatment Cost Comparison: India vs Global
India offers the most affordable access to standard myeloma drugs globally. For BCMA CAR-T, China is the current affordable alternative to USA/EU pricing.
Daratumumab Per Cycle
- India (biosimilar)$3,000
- China$8,000
- USA$15,000
- EU/UK$12,000
BCMA CAR-T (One-Time)
- India (NexCAR19 โ not applicable)N/A
- China (carvykti biosimilar)$80,000
- USA (carvykti branded)$475,000
- EU$350,000
Key Numbers: India BCMA CAR-T Pipeline
- 0Commercially Approved BCMA CAR-T Products in India (2026)No BCMA CAR-T product has received CDSCO commercial approval as of June 2026.
- 2027โ28Earliest Projected Indian BCMA Commercial LaunchImmunoACT BCMA programme requires Phase I completion and CDSCO review before commercial use.
- >10Active BCMA CAR-T Trials in China (2026)Multiple Chinese centres running BCMA and dual-target myeloma CAR-T trials with international patient access.
- ~$80KBCMA CAR-T Cost in China (carvykti biosimilar)Approximately $80,000 USD all-in for BCMA CAR-T treatment in China โ vs $475,000 in the USA.
CancerFax India-to-China Escalation for Myeloma
CancerFax has a dedicated pathway for myeloma patients who have exhausted standard Indian options and require BCMA CAR-T or dual-target access via China.
Case Eligibility Review
CancerFax reviews myeloma history, prior lines (daratumumab exposure, proteasome inhibitor, IMiD), cytogenetics (high-risk del17p, t(4;14)), BCMA expression, and performance status to identify optimal Chinese programme.
Ruijin Hospital Shanghai
Ruijin Hospital runs active BCMA+GPRC5D dual CAR-T trials. CancerFax coordinates with the haematology team at Ruijin for trial eligibility pre-screening before the patient travels.
SYSUCC Guangzhou
Sun Yat-sen University Cancer Centre (SYSUCC) Guangzhou also runs myeloma CAR-T programmes. CancerFax can coordinate parallel enquiries to identify the best-fit programme.
Logistics
CancerFax manages Chinese medical visa (M visa) application support, interpreter coordination, and in-country logistics for India-origin myeloma patients travelling to China.
More from the CAR-T India Resource Library
Explore related guides on India's CAR-T landscape, costs, and escalation pathways to China for myeloma.
Frequently Asked Questions โ BCMA CAR-T and Myeloma in India
Can I get BCMA CAR-T in India in 2026?
No commercial BCMA CAR-T product is approved in India as of 2026. The only approved CAR-T product in India is NexCAR19, which targets CD19 and is not indicated for myeloma. The ImmunoACT BCMA pipeline is in early development. For BCMA CAR-T access today, China is the most accessible option globally at $80,000 compared to $475,000 in the USA.
Is daratumumab available in India for myeloma?
Yes โ daratumumab biosimilar is commercially available at Indian cancer centres at approximately $2,000โ4,000 per cycle, compared to $15,000+ in the USA. VRd and DRd regimens are standard of care at leading centres including Tata Memorial, Apollo, CMC Vellore, and AIIMS. This makes India one of the best destinations globally for affordable myeloma drug therapy.
When will BCMA CAR-T be available in India?
The most optimistic projection is 2027โ2028 for commercial availability of a BCMA CAR-T product in India, based on ImmunoACT's disclosed development timeline and the typical CDSCO review process. This is an estimate subject to trial outcomes and regulatory decisions. Patients with active relapsed myeloma cannot wait for this timeline and should explore China.
What is a dual-target CAR-T for myeloma?
Dual-target CAR-T constructs contain two targeting domains โ typically BCMA+GPRC5D or BCMA+CD38 โ designed to reduce antigen escape (where myeloma cells downregulate one target). These are not yet available in India and are currently only accessible via clinical trials in China and some Western academic centres. CancerFax can review your case for dual-target trial eligibility.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Relapsed Myeloma and Exploring CAR-T Options?
CancerFax reviews your myeloma history and helps identify whether China-based BCMA or dual-target CAR-T programmes are appropriate for your case.
This content is for informational purposes only and does not constitute medical advice. Treatment decisions should be made in consultation with your haematologist.